[{"from": "human", "value": "Please give me some details about this molecule. [C][C][C][=C][Branch2][Ring2][=Branch2][C][=C][C][C][Branch1][Branch2][C][C][Ring1][Branch1][=C][Ring1][=Branch2][N][C][C@@H1][Branch2][Ring1][Branch1][C][=C][C][=C][C][=Branch1][C][=O][N][C][Ring1][#Branch1][=C][Branch1][Branch1][C][=C][Ring1][O][O][O][C][C]"}, {"from": "gpt", "value": "The molecule is a novel, ultra-long-acting, rapid onset \u03b2(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed."}]